{
    "headline": "Protalix BioTherapeutics and Chiesi\nGlobal Rare Diseases Announce\nTopline Results from the 24-Month\nPhase III BALANCE Clinical Trial of\nPRX-102 for the Treatment of Fabry\n",
    "publish_date": "04/04/22 5:50 AM",
    "content": "CARMIEL, Israel and BOSTON, April 4, 2022 /\nPRNewswire/ -- Protalix BioTherapeutics,\n\nInc. (NYSE American: PLX) (TASE: PLX), a\nbiopharmaceutical company focused on the\ndevelopment, production and commercialization\nof recombinant therapeutic proteins produced\n\nby its proprietary Ser ae plant cell-based\nprotein expression system, and Chiesi Global\nRare Diseases, a business unit of Chiesi\nFarmaceutici S.p.A., an international research\nfocused healthcare Group (Chiesi Group),\n\ntoday announced topline results from the\nBALANCE pivotal Phase Ill clinical trial evaluating\npegunigalsidase alfa (PRX-102), 1 mg/kg,\nadministered every two weeks, compared to\nagalsidase beta (eae for the treatment\nof Fabry disease. PRX-102 is a novel, PEGylated\nenzyme replacement therapy (ERT) under\ndevelopment for the treatment of Fabry disease."
}
